Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

PD-L1 Expression Remains Primary Guide for NSCLC Treatment Selection in the Absence of Targetable Mutations

August 5th 2024

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

Refining Adjuvant Immunotherapy Use Is a Crucial Focus in Early-Stage NSCLC

August 2nd 2024

Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.

BTK Degraders and Fixed-Duration Regimens May Represent the Future in CLL

August 2nd 2024

Alexey Danilov, MD, PhD, highlights the evolution of targeting BTK, sharing new data on BTK degraders and more in chronic lymphocytic leukemia

Clinically Guided Cannabis Use Helps Mitigate Symptoms Experienced by Patients With Cancer

August 1st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, highlight the importance of personalized cannabis use in alleviating treatment-related symptoms.

Integrated 15-GEP and PRAME Classifier Shows Prognostic Accuracy in Uveal Melanoma

August 1st 2024

Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma.

Minimal Residual Disease Status Displays Association with PFS in CLL

August 1st 2024

Minimal residual disease status was associated with progression-free survival in chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Model Validates Cost Savings With Cannabis in Mitigating Symptoms for Patients With Cancer

July 31st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, detail a health care cost impacts model pertaining to the use of cannabis for therapy-related symptoms

NCCN Recommends Imetelstat for Symptomatic Anemia in Lower-Risk MDS

July 31st 2024

The National Comprehensive Cancer Network has issued category 1 and 2A recommendations for imetelstat as therapy for symptomatic anemia in patients with lower-risk MDS.

Two Leading Experts Detail Hot Topics in GI Cancers to Be Presented at Upcoming ISGIO Meeting

July 31st 2024

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.

Uzzo Elucidates the Potential Role of KIM-1 as a Biomarker in RCC

July 30th 2024

Robert Uzzo, MD, details data from the IMmotion010 study on KIM-1 and how the biomarker could be used as well as future directions for investigating it in RCC.

Tolaney Details IHC Testing Considerations for HER2-Low TNBC and Data on ADCs

July 29th 2024

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

July 26th 2024

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26th 2024

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

Fecal Microbiota Transplants May Enhance Immunotherapy Efficacy in GI Cancers

July 25th 2024

Donor fecal microbiota transplants increased the activity of immunotherapy in patients with GI cancers.

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

July 24th 2024

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer.

RAS-Directed Therapy and Patient Selection Are Sectors to Watch in Pancreatic Cancer

July 24th 2024

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

July 24th 2024

An EHR-based prompt or “nudge” decreased the rates of sentinel lymph node biopsy among older patients with early-stage breast cancer.

Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line

July 24th 2024

Adrienne G. Waks, MD, details her approach to treatment sequencing in metastatic HER2-positive disease and the potential role of T-DXd in the first line.

Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?

July 23rd 2024

Adrienne G. Waks, MD, parses out recent and upcoming data in HER2+ breast cancer and discusses why abbreviated neoadjuvant regimens are not ready for primetime.

KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC

July 21st 2024

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.